Shares of Jupiter Neurosciences Inc jumped sharply in premarket trading after the company disclosed it had entered into a term sheet to acquire exclusive U.S. licensing rights to ALA-002, a next-generation MDMA-based therapeutic candidate, from PharmAla Biotech Holdings Inc.
Jupiter will pay $3.33 million as upfront consideration under the term sheet. That amount is composed of $1.50 million in cash and $1.83 million in Jupiter common stock, payable at closing. The stock component will be subject to a 120-day lock-up period. Upon execution of the term sheet, Jupiter placed $600,000 into an escrow account; that sum will be credited against the upfront cash payment at closing. If the parties do not execute a definitive agreement within 90 days, PharmAla will receive the escrowed funds as a reverse termination fee, subject to certain exceptions spelled out in the term sheet.
ALA-002 is described in the term sheet as a patented, non-racemic MDMA formulation that the Food and Drug Administration has recognized as a Novel Chemical Entity. According to the companies' disclosures, the compound has been engineered to offer improved cardiovascular safety and reduced abuse liability compared with racemic MDMA while maintaining the therapeutic characteristics that are central to MDMA-assisted therapy.
The announcement came against a backdrop of recent federal direction to accelerate investigational psychedelic therapies. The term sheet references the April 18, 2026 Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness," which directed the FDA and the Drug Enforcement Administration to expand access to investigational psychedelic therapies, established a Right to Try Pathway for investigational psychedelic drugs and allocated $50 million through the Advanced Research Projects Agency for Health to support psychedelic medicine programs.
Investors reacted quickly to the licensing announcement, lifting Jupiter shares sharply in premarket trading. Company statements caution that completion of the transaction remains conditional. The term sheet specifies that the deal is subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of required corporate and regulatory approvals and satisfaction of other customary closing conditions.
Summary
Jupiter Neurosciences has entered a binding term sheet to acquire exclusive U.S. rights to ALA-002 from PharmAla Biotech for $3.33 million upfront consideration. A $600,000 escrow deposit has been made and will be credited at closing, or paid to PharmAla as a reverse termination fee if a definitive agreement is not reached within 90 days under specified exceptions. ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity and is described as engineered to reduce cardiovascular risk and abuse liability while retaining therapeutic effects.
Key points
- Jupiter announced a term sheet to acquire exclusive U.S. licensing rights to ALA-002 from PharmAla, triggering a 75.9% premarket share increase.
- Upfront consideration totals $3.33 million - $1.50 million in cash and $1.83 million in Jupiter common stock, with the equity component locked for 120 days.
- The transaction is conditional on due diligence, definitive agreement execution, corporate and regulatory approvals, and other customary closing conditions; the deal references recent federal initiatives to expand investigational psychedelic therapy access and funding.
Risks and uncertainties
- The transaction remains subject to completion of due diligence and the negotiation and execution of definitive agreements - a process that could prevent the deal from closing.
- Receipt of required corporate and regulatory approvals is not guaranteed; regulatory review processes could delay or block the transaction.
- If a definitive agreement is not reached within 90 days, PharmAla may retain the $600,000 escrowed deposit as a reverse termination fee, subject to exceptions, which could affect the economics of the proposed transaction and investor perceptions.